Download Report

Working document QAS/13.521/Rev.3
August 2014
Document for comment
1
2
3
4
5
GENERAL GUIDANCE
6
ON “HOLD-TIME” STUDIES
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
REVISED DRAFT FOR COMMENT
(August 2014)
Should you have any comments on the attached text, please send these to
Dr Sabine Kopp, Group Lead, Medicines Quality Assurance, Technologies, Standards
and Norms, World Health Organization, 1211 Geneva 27, Switzerland; email:
[email protected]; fax: (+41 22) 791 4730 ([email protected]) and to Ms Marie Gaspard
([email protected]), by 30 September 2014.
Working documents are sent out electronically and they will also be placed on the
Medicines web site for comment. If you do not already receive directly our draft
guidelines please let us have your e-mail address (to [email protected]) and we will
add it to our electronic mailing list.
___________________________________________________________________________
© World Health Organization 2014
All rights reserved.
This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The
draft may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in
whole, in any form or by any means outside these individuals and organizations (including the organizations' concerned
staff and member organizations) without the permission of the World Health Organization. The draft should not be
displayed on any website.
Please send any request for permission to:
Dr Sabine Kopp, Group Lead, Medicines Quality Assurance, Technologies, Standards and Norms, Department of
Essential Medicines and Health Products, World Health Organization, CH-1211 Geneva 27, Switzerland. Fax: (41-22)
791 4730; email: [email protected].
The designations employed and the presentation of the material in this draft do not imply the expression of any opinion
whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or
area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent
approximate border lines for which there may not yet be full agreement.
The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or
recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
All reasonable precautions have been taken by the World Health Organization to verify the information contained in
this draft. However, the printed material is being distributed without warranty of any kind, either expressed or implied.
The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health
Organization be liable for damages arising from its use.
This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.
Working document QAS/13.521/Rev.3
page 2
47
48
SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/13.521
GENERAL GUIDANCE ON “HOLD-TIME” STUDIES
49
Date
Preparation of draft by Dr A.J. van Zyl,
South Africa, based on need identified by
the WHO Prequalification Programme
inspectors
November-December 2012
Preliminary internal review of draft
January 2013
Draft mailed for comments
February 2013
Collation of comments
April 2013
Review by inspectors collaborating with the May 2013
WHO Prequalification Programme
Discussion during the joint informal
consultation with Prequalification
Inspection team and inspectors from
national inspectorates
30 May 2013
Follow-up of e-Discussion of Subgroup
with expert inspectors to finalize new draft
of working document for comments
June 2013
Recirculation of working document for
comments
July 2013
Compilation of comments and feedback
September 2013
Review of feedback received with
Prequalification Inspection team
September 2013
Presentation to forty-eighth meeting of the 14-18 October 2013
WHO Expert Committee on Specifications
for Pharmaceutical Preparations
Review of comments with subgroup of
WHO Expert Committee on Specifications
for Pharmaceutical Preparations and
subsequently with Dr A.J. van Zyl and the
Prequalification Team – Inspections Group
October 2013–January 2014
Working document QAS/13.521/Rev.3
page 3
Further follow-up action as required
…
Recirculation of working document for
comments
February 2014
Compilation of comments
April 2014
Discussion of feedback during informal
consultation on medicines quality: GXPs,
inspection guides and risk management
28-30 April 2014
Recirculation of updated working
document
August 2014
Compilation of comments and evaluation of End September 2014
feedback received
50
51
Presentation to forty-ninth meeting of the
WHO Expert Committee on Specifications
for Pharmaceutical Preparations
October 2014
Further follow-up action as required
…
Working document QAS/13.521/Rev.3
page 4
52
GENERAL GUIDANCE ON “HOLD-TIME” STUDIES
53
54
CONTENTS
55
56
1. INTRODUCTION AND BACKGROUND
57
2. GLOSSARY
58
3. SCOPE
59
4. ASPECTS TO BE CONSIDERED
60
61
62
63
64
1.
INTRODUCTION AND BACKGROUND
65
66
Manufacturers should ensure that the products that they manufacture are safe, effective
67
and of the quality required for their intended use. Products should be consistently
68
manufactured to the quality standards appropriate to their intended use and as required by
69
the marketing authorization. Systems should ensure that pharmaceutical products are
70
produced according to validated processes and to defined procedures. Manufacturing
71
processes should be shown to be capable of consistently manufacturing pharmaceutical
72
products of the required quality that comply with their specifications.
73
74
Arrangements should exist to ensure that the dispensed raw materials and packaging
75
materials, intermediate products, bulk and finished products are stored under appropriate
76
conditions. Storage should not have any significant negative effect on the processing,
77
stability, safety, efficacy or quality of the materials, intermediate products and bulk
78
products prior to final packing. Good manufacturing practices (GMP) require that a
79
maximum acceptable holding period should be established to ensure that intermediates
80
and bulk product can be held, pending the next processing step, without any significant
Working document QAS/13.521/Rev.3
page 5
81
adverse effect to the quality of the material. Such a holding period should be underwritten
82
by data, but need not be extended to find the edge of failure.
83
84
2. GLOSSARY
85
86
Bulk product
87
Any pharmaceutical product which has completed all processing stages up to, but not
88
including, final packaging.
89
90
Intermediate
91
Partly processed product that must undergo further manufacturing steps before it becomes
92
a bulk product.
93
94
3.
SCOPE
95
96
This guideline focus primarily on aspects that should be considered in the design of the
97
hold-time studies during the manufacture of solid dosage forms. Many of the principles
98
herein also apply to other dosage forms such as liquids, creams and ointments. This
99
guideline does not cover aspects for hold times in cleaning validation or the
100
manufacturing of active pharmaceutical ingredients (APIs).
101
102
This guideline is intended as a basic guide for use by pharmaceutical manufacturers and
103
GMP inspectors. This document does not intend to prescribe a process for establishing
104
hold times, but reflects aspects that should be considered in the design of the hold-time
105
study.
106
107
Manufacturers should gather scientific and justifiable data to demonstrate that the
108
dispensed raw materials and packaging materials, intermediate and bulk products:
109
110
-
remain of appropriate quality before processing to the next stage;
Working document QAS/13.521/Rev.3
page 6
111
-
meet the acceptance criteria and release specification for the finished product.
112
113
4.
ASPECTS TO BE CONSIDERED
114
115
Hold time can be considered as the established time period for which materials
116
(dispensed raw materials, intermediates and bulk dosage form awaiting final packaging)
117
may be held under specified conditions and will remain within the defined specifications.
118
119
Data to justify the hold time can be collected, but not limited to:
120
-
during development on pilot-scale batches,
121
-
during scale up,
122
-
during process validation, or
123
-
as part of an investigation of a deviation that occurred during manufacture.
124
Hold-time studies establish the time limits for holding the materials at different stages of
125
production to ensure that the quality of the product does not deteriorate significantly
126
during the hold time. The design of the study should reflect the holding time at each
127
stage. Hold times should normally be determined prior to marketing of a product and
128
following any significant changes in processes, equipment, starting and packaging
129
materials and represent actual processing. Hold time studies should be included during
130
process validation (Ref: Process validation guideline).
131
132
Manufacturers may use a flow chart to review the manufacturing procedure of a product
133
and then break up the critical stages of manufacturing process on the basis of time
134
duration required for the particular storage and processing stages, typical pauses in the
135
manufacturing campaign, and the potential impact of storage with reference to
136
environmental and storage conditions. An example for a flow chart is given below.
137
138
For example, for oral tablets that are coated the following stages may be considered:
139
140
-
binder preparation to granulation – consider the granulate;
Working document QAS/13.521/Rev.3
page 7
141
-
wet granulation to drying – the dried granulate;
142
-
dried granules to lubrication/blending – the lubricated blend;
143
-
blend to compression;
144
-
compression to coating – the tablet cores;
145
-
coating solution to preparation – the coating solution;
146
-
coating to packing – consider the bulk coated tablets;
147
-
coating to packing in bulk or FDF;
148
-
packing in bulk to FDF.
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
Example for a flow chart :
Dispensing
Sifting
Dry
Mixing
Granules:
Sample withdrawn for
analysis
Granulation
Binder
Sample withdrawn for
analysis
Drying
Lubrication
&Blending
Blend:
Sample withdrawn for
analysis
Core tablets:
Sample withdrawn for
analysis
Compression
Coated tablet:
Sample withdrawn for
analysis
Coating
Packing
Drying
Coating Solution:
Sample withdrawn for
analysis
Working document QAS/13.521/Rev.3
page 8
181
182
A written protocol, procedure or programme should be followed which includes the
183
activities to be performed, test parameters and acceptance criteria appropriate to the
184
material or product under test. The protocol and report should generally include the
185
following: a title; reference number; version; date; objective; scope; responsibility;
186
procedure; description of the material/product; sample quantities; sampling method and
187
criteria; acceptance limits; frequency for sampling; sampling locations; pooling of
188
samples; storage conditions; type of container; methods of analysis; results; conclusion;
189
recommendation; signatures and dates. Acceptance criteria are typically more stringent
190
than registered specifications to provide assurance that the material is well within control.
191
When setting the specifications any known stability trends will need to be taken into
192
account.
193
194
For certain products microbiological aspects should also be considered and included
195
where appropriate.
196
197
Typically one or more batches of a material, intermediate or product can be used for
198
determining hold times. A risk-based approach can be used to determine the appropriate
199
number of batches, considering inter alia the characteristics of the materials A
200
representative sample of the batch of material or product subjected to the hold-time study
201
should be held for the defined hold period. The maximum hold period for each category
202
of material should be established on the basis of the study by keeping the material in
203
either the original or simulated container used in production. The containers used in
204
which hold-time samples are stored should be the same pack as used in production unless
205
the pack is exceptionally large, in which case one that is equivalent (same material of
206
construction and closure system to the production packaging system) may be used.
207
Reducing the size of container when necessary for testing holding time, should be
208
justified. Where head space is important the hold-time samples should represent the
209
maximum
210
manufacturing/quarantine. The sample storage environmental conditions should be same
211
as that of the quarantine area/manufacture stage.Asampling plan should be established
possible
head
space
(worst-case
scenario)
to
bulk
stored
in
Working document QAS/13.521/Rev.3
page 9
212
and followed for taking samples for testing at the different intervals. The required sample
213
amount should be calculated based on the batch size, the intervals and tests to be
214
performed. Results should be compared with the initial baseline data of the control
215
sample . Samples may be pooled for analysis where appropriate, e.g. when the analysis of
216
a composite sample will not miss issues expected in the variation of the product.
217
218
Where appropriate, statistical analysis of the data generated should be performed to
219
identify trends and to justify the limits and hold time set.
220
221
Batches of finished products made from intermediates or bulk products and subjected to a
222
hold-time study should be considered for long-term stability testing if data show adverse
223
trending or shifting patterns during the intermediate time points up to the end of the
224
shelf-life. The shelf-life of the product – irrespective of hold times – should be measured
225
from the time the active ingredients are mixed with other ingredients. Normally
226
intermediate and bulk products should not be stored beyond the established hold time. All
227
testing of bulk intermediates and product should be performed using validated stability-
228
indicating methods.
229
230
The following table provides examples of stages and tests that may be considered.
231
232
Table: Examples of stages and tests that may be considered, based on risk assessment
233
and specific product needs
Stage
Test to be carried out as per
specification
Study time
Binder preparation
Microbial test
Initial, 2hrs, 5hrs, 8hrs.
In case of starch: initial,
2hrs, 5hrs
Solution prepared
(including granulation
pastes, coating solution
and coating suspensión
Physical appearance, Specific
gravity, Viscosity, Sedimentation,
pH, Microbial test
Initial, 12, 24, 36, 48,
60, 72 hours
Working document QAS/13.521/Rev.3
page 10
Granule
Description, Assay, Related
substances, Loss on drying, Water
content, Particle size distribution,
Bulk density, Tap density, Angle
of repose.
Initial, 30th day, 45th
day
Blend
Microbial test, Loss on drying,
Blend uniformity, Particle size,
Bulk/Tapped density
Initial, 30th day, 45th
day
Core tablets – uncoated
(in bulk container
Description, Hardness, Thickness,
Friability, Disintegration,
Dissolution or Dissolution profile,
assay, Degradation products/
related substance, Uniformity of
dosage units, Microbial test.
Description, Hardness, Thickness,
Friability, Disintegration,
Dissolution or Dissolution profile,
Assay, Degradation products/
related substance, Uniformity of
dosage units , Moisture content,
Microbial test.
Initial, 30th day, 60th
day & 90th day
Coated tablets (in bulk
container)
234
235
236
***
Initial, 30th day, 60th
day & 90th day